Clinical Trial Update: Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

A Phase 2 trial update on high-dose pulse DN-101 (calcitriol) for patients with myelodysplastic syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• DN-101 (calcitriol) (calcitriol)

Snippet

Sponsor: Novacea | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: UNKNOWN